<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39340098</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2076-393X</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>9</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>18</Day></PubDate></JournalIssue><Title>Vaccines</Title><ISOAbbreviation>Vaccines (Basel)</ISOAbbreviation></Journal><ArticleTitle>Adjuvant Use of the Invariant-Natural-Killer-T-Cell Agonist α-Galactosylceramide Leads to Vaccine-Associated Enhanced Respiratory Disease in Influenza-Vaccinated Pigs.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1068</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/vaccines12091068</ELocationID><Abstract><AbstractText>Invariant natural killer T (iNKT) cells are glycolipid-reactive T cells with potent immunoregulatory properties. iNKT cells activated with the marine-sponge-derived glycolipid, α-galactosylceramide (αGC), provide a universal source of T-cell help that has shown considerable promise for a wide array of therapeutic applications. This includes harnessing iNKT-cell-mediated immune responses to adjuvant whole inactivated influenza virus (WIV) vaccines. An important concern with WIV vaccines is that under certain circumstances, they are capable of triggering vaccine-associated enhanced respiratory disease (VAERD). This immunopathological phenomenon can arise after immunization with an oil-in-water (OIW) adjuvanted WIV vaccine, followed by infection with a hemagglutinin and neuraminidase mismatched challenge virus. This elicits antibodies (Abs) that bind immunodominant epitopes in the HA2 region of the heterologous virus, which purportedly causes enhanced virus fusion activity to the host cell and increased infection. Here, we show that αGC can induce severe VAERD in pigs. However, instead of stimulating high concentrations of HA2 Abs, αGC elicits high concentrations of interferon (IFN)-γ-secreting cells both in the lungs and systemically. Additionally, we found that VAERD mediated by iNKT cells results in distinct cytokine profiles and altered adaptation of the challenge virus following infection compared to an OIW adjuvant. Overall, these results provide a cautionary note about considering the formulation of WIV vaccines with iNKT-cell agonists as a potential strategy to modulate antigen-specific immunity.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Artiaga</LastName><ForeName>Bianca L</ForeName><Initials>BL</Initials><AffiliationInfo><Affiliation>Department of Diagnostic Medicine &amp; Pathobiology, College of Veterinary Medicine, Kansas State University, Manhattan, KS 66506, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Madden</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Diagnostic Medicine &amp; Pathobiology, College of Veterinary Medicine, Kansas State University, Manhattan, KS 66506, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kwon</LastName><ForeName>Taeyong</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Diagnostic Medicine &amp; Pathobiology, College of Veterinary Medicine, Kansas State University, Manhattan, KS 66506, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McDowell</LastName><ForeName>Chester</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0001-8452-7288</Identifier><AffiliationInfo><Affiliation>Department of Diagnostic Medicine &amp; Pathobiology, College of Veterinary Medicine, Kansas State University, Manhattan, KS 66506, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Keating</LastName><ForeName>Cassidy</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Diagnostic Medicine &amp; Pathobiology, College of Veterinary Medicine, Kansas State University, Manhattan, KS 66506, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Balaraman</LastName><ForeName>Velmurugan</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0003-1671-5572</Identifier><AffiliationInfo><Affiliation>Department of Diagnostic Medicine &amp; Pathobiology, College of Veterinary Medicine, Kansas State University, Manhattan, KS 66506, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Carvahlo Madrid</LastName><ForeName>Darling Melany</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Division of Animal Sciences, University of Missouri, Columbia, MO 65211, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Bond Life Sciences Center, University of Missouri, Columbia, MO 65211, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Touchard</LastName><ForeName>Laurie</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Division of Animal Sciences, University of Missouri, Columbia, MO 65211, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Bond Life Sciences Center, University of Missouri, Columbia, MO 65211, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Henningson</LastName><ForeName>Jamie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Diagnostic Medicine &amp; Pathobiology, College of Veterinary Medicine, Kansas State University, Manhattan, KS 66506, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meade</LastName><ForeName>Philip</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Center for Vaccine Research and Pandemic Preparedness (C-VaRPP), Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Krammer</LastName><ForeName>Florian</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0003-4121-776X</Identifier><AffiliationInfo><Affiliation>Center for Vaccine Research and Pandemic Preparedness (C-VaRPP), Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Ignaz Semmelweis Institute, Interuniversity Institute for Infection Research, Medical University of Vienna, 1090 Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morozov</LastName><ForeName>Igor</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Diagnostic Medicine &amp; Pathobiology, College of Veterinary Medicine, Kansas State University, Manhattan, KS 66506, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Richt</LastName><ForeName>Juergen A</ForeName><Initials>JA</Initials><Identifier Source="ORCID">0000-0001-7308-5672</Identifier><AffiliationInfo><Affiliation>Department of Diagnostic Medicine &amp; Pathobiology, College of Veterinary Medicine, Kansas State University, Manhattan, KS 66506, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Driver</LastName><ForeName>John P</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Division of Animal Sciences, University of Missouri, Columbia, MO 65211, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Bond Life Sciences Center, University of Missouri, Columbia, MO 65211, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>1R01AI092286-02A1</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1R01AI158477-02A1</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>2021-67015</GrantID><Agency>U.S. Department of Agriculture</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Vaccines (Basel)</MedlineTA><NlmUniqueID>101629355</NlmUniqueID><ISSNLinking>2076-393X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">adjuvants</Keyword><Keyword MajorTopicYN="N">influenza A virus</Keyword><Keyword MajorTopicYN="N">natural killer T cell</Keyword><Keyword MajorTopicYN="N">swine</Keyword><Keyword MajorTopicYN="N">vaccine</Keyword><Keyword MajorTopicYN="N">vaccine-associated enhanced respiratory disease</Keyword><Keyword MajorTopicYN="N">α-galactosylceramide</Keyword></KeywordList><CoiStatement>The JR laboratory received support from Tonix Pharmaceuticals, Genus plc, Xing Technologies, and Zoetis, outside of the reported work. JR is an inventor on patents and patent applications on the use of antivirals and vaccines for the treatment and prevention of viral infections, owned by Kansas State University. The Icahn School of Medicine at Mount Sinai has filed patent applications relating to SARS-CoV-2 serological assays, NDV-based SARS-CoV-2 vaccines, influenza virus vaccines, and influenza virus therapeutics, which list FK as co-inventor. Mount Sinai has spun out a company, Kantaro, to market serological tests for SARS-CoV-2 and another company, CastleVax, to develop SARS-CoV-2 vaccines. FK is co-founder and scientific advisory board member of CastleVax. FK has consulted for Merck, Curevac, Seqirus, and Pfizer and is currently consulting for 3rd Rock Ventures, GSK, Gritstone, and Avimex. The Krammer laboratory is collaborating with Dynavax on influenza vaccine development. The other authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>1</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39340098</ArticleId><ArticleId IdType="pmc">PMC11435877</ArticleId><ArticleId IdType="doi">10.3390/vaccines12091068</ArticleId><ArticleId IdType="pii">vaccines12091068</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Taylor A., Foo S.S., Bruzzone R., Vu Dinh L., King N.J., Mahalingam S. Fc receptors in antibody-dependent enhancement of viral infections. Immunol. Rev. 2015;268:340–364. doi: 10.1111/imr.12367.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imr.12367</ArticleId><ArticleId IdType="pmc">PMC7165974</ArticleId><ArticleId IdType="pubmed">26497532</ArticleId></ArticleIdList></Reference><Reference><Citation>Takada A., Kawaoka Y. Antibody-dependent enhancement of viral infection: Molecular mechanisms and in vivo implications. Rev. Med. Virol. 2003;13:387–398. doi: 10.1002/rmv.405.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rmv.405</ArticleId><ArticleId IdType="pubmed">14625886</ArticleId></ArticleIdList></Reference><Reference><Citation>Smatti M.K., Al Thani A.A., Yassine H.M. Viral-Induced Enhanced Disease Illness. Front. Microbiol. 2018;9:2991. doi: 10.3389/fmicb.2018.02991.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2018.02991</ArticleId><ArticleId IdType="pmc">PMC6290032</ArticleId><ArticleId IdType="pubmed">30568643</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobinger G.P., Meunier I., Patel A., Pillet S., Gren J., Stebner S., Leung A., Neufeld J.L., Kobasa D., von Messling V. Assessment of the efficacy of commercially available and candidate vaccines against a pandemic H1N1 2009 virus. J. Infect. Dis. 2010;201:1000–1006. doi: 10.1086/651171.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/651171</ArticleId><ArticleId IdType="pmc">PMC7109664</ArticleId><ArticleId IdType="pubmed">20170374</ArticleId></ArticleIdList></Reference><Reference><Citation>Vincent A.L., Lager K.M., Janke B.H., Gramer M.R., Richt J.A. Failure of protection and enhanced pneumonia with a US H1N2 swine influenza virus in pigs vaccinated with an inactivated classical swine H1N1 vaccine. Vet. Microbiol. 2008;126:310–323. doi: 10.1016/j.vetmic.2007.07.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vetmic.2007.07.011</ArticleId><ArticleId IdType="pubmed">17719188</ArticleId></ArticleIdList></Reference><Reference><Citation>Gauger P.C., Vincent A.L., Loving C.L., Henningson J.N., Lager K.M., Janke B.H., Kehrli M.E., Roth J.A. Kinetics of lung lesion development and pro-inflammatory cytokine response in pigs with vaccine-associated enhanced respiratory disease induced by challenge with pandemic (2009) A/H1N1 influenza virus. Vet. Pathol. 2012;49:900–912. doi: 10.1177/0300985812439724.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0300985812439724</ArticleId><ArticleId IdType="pubmed">22461226</ArticleId></ArticleIdList></Reference><Reference><Citation>Gauger P.C., Vincent A.L., Loving C.L., Lager K.M., Janke B.H., Kehrli M.E., Roth J.A. Enhanced pneumonia and disease in pigs vaccinated with an inactivated human-like (δ-cluster) H1N2 vaccine and challenged with pandemic 2009 H1N1 influenza virus. Vaccine. 2011;29:2712–2719. doi: 10.1016/j.vaccine.2011.01.082.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2011.01.082</ArticleId><ArticleId IdType="pubmed">21310191</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimble J.B., Wymore Brand M., Kaplan B.S., Gauger P., Coyle E.M., Chilcote K., Khurana S., Vincent A.L. Vaccine-Associated Enhanced Respiratory Disease following Influenza Virus Infection in Ferrets Recapitulates the Model in Pigs. J. Virol. 2022;96:e0172521. doi: 10.1128/jvi.01725-21.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.01725-21</ArticleId><ArticleId IdType="pmc">PMC8906406</ArticleId><ArticleId IdType="pubmed">34985999</ArticleId></ArticleIdList></Reference><Reference><Citation>Ochiai H., Kurokawa M., Hayashi K., Niwayama S. Antibody-mediated growth of influenza A NWS virus in macrophagelike cell line P388D1. J. Virol. 1988;62:20–26. doi: 10.1128/jvi.62.1.20-26.1988.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.62.1.20-26.1988</ArticleId><ArticleId IdType="pmc">PMC250496</ArticleId><ArticleId IdType="pubmed">3334744</ArticleId></ArticleIdList></Reference><Reference><Citation>Ochiai H., Kurokawa M., Kuroki Y., Niwayama S. Infection enhancement of influenza A H1 subtype viruses in macrophage-like P388D1 cells by cross-reactive antibodies. J. Med. Virol. 1990;30:258–265. doi: 10.1002/jmv.1890300406.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.1890300406</ArticleId><ArticleId IdType="pubmed">2370521</ArticleId></ArticleIdList></Reference><Reference><Citation>Monsalvo A.C., Batalle J.P., Lopez M.F., Krause J.C., Klemenc J., Hernandez J.Z., Maskin B., Bugna J., Rubinstein C., Aguilar L., et al. Severe pandemic 2009 H1N1 influenza disease due to pathogenic immune complexes. Nat. Med. 2011;17:195–199. doi: 10.1038/nm.2262.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.2262</ArticleId><ArticleId IdType="pmc">PMC3034774</ArticleId><ArticleId IdType="pubmed">21131958</ArticleId></ArticleIdList></Reference><Reference><Citation>Skowronski D.M., De Serres G., Crowcroft N.S., Janjua N.Z., Boulianne N., Hottes T.S., Rosella L.C., Dickinson J.A., Gilca R., Sethi P., et al. Association between the 2008-09 seasonal influenza vaccine and pandemic H1N1 illness during Spring-Summer 2009: Four observational studies from Canada. PLoS Med. 2010;7:e1000258. doi: 10.1371/journal.pmed.1000258.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1000258</ArticleId><ArticleId IdType="pmc">PMC2850386</ArticleId><ArticleId IdType="pubmed">20386731</ArticleId></ArticleIdList></Reference><Reference><Citation>Janjua N.Z., Skowronski D.M., Hottes T.S., Osei W., Adams E., Petric M., Sabaiduc S., Chan T., Mak A., Lem M., et al. Seasonal influenza vaccine and increased risk of pandemic A/H1N1-related illness: First detection of the association in British Columbia, Canada. Clin. Infect. Dis. 2010;51:1017–1027. doi: 10.1086/656586.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/656586</ArticleId><ArticleId IdType="pmc">PMC7107856</ArticleId><ArticleId IdType="pubmed">20887210</ArticleId></ArticleIdList></Reference><Reference><Citation>Khurana S., Loving C.L., Manischewitz J., King L.R., Gauger P.C., Henningson J., Vincent A.L., Golding H. Vaccine-induced anti-HA2 antibodies promote virus fusion and enhance influenza virus respiratory disease. Sci. Transl. Med. 2013;5:200ra114. doi: 10.1126/scitranslmed.3006366.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.3006366</ArticleId><ArticleId IdType="pubmed">23986398</ArticleId></ArticleIdList></Reference><Reference><Citation>Souza C.K., Rajão D.S., Sandbulte M.R., Lopes S., Lewis N.S., Loving C.L., Gauger P.C., Vincent A.L. The type of adjuvant in whole inactivated influenza a virus vaccines impacts vaccine-associated enhanced respiratory disease. Vaccine. 2018;36:6103–6110. doi: 10.1016/j.vaccine.2018.08.072.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2018.08.072</ArticleId><ArticleId IdType="pubmed">30181048</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajão D.S., Loving C.L., Gauger P.C., Kitikoon P., Vincent A.L. Influenza A virus hemagglutinin protein subunit vaccine elicits vaccine-associated enhanced respiratory disease in pigs. Vaccine. 2014;32:5170–5176. doi: 10.1016/j.vaccine.2014.07.059.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2014.07.059</ArticleId><ArticleId IdType="pubmed">25077416</ArticleId></ArticleIdList></Reference><Reference><Citation>Gauger P.C., Loving C.L., Lager K.M., Janke B.H., Kehrli M.E., Jr., Roth J.A., Vincent A.L. Vaccine-associated enhanced respiratory disease does not interfere with the adaptive immune response following challenge with pandemic A/H1N1 2009. Viral Immunol. 2013;26:314–321. doi: 10.1089/vim.2013.0018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/vim.2013.0018</ArticleId><ArticleId IdType="pubmed">24033080</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajão D.S., Chen H., Perez D.R., Sandbulte M.R., Gauger P.C., Loving C.L., Shanks G.D., Vincent A. Vaccine-associated enhanced respiratory disease is influenced by haemagglutinin and neuraminidase in whole inactivated influenza virus vaccines. J. Gen. Virol. 2016;97:1489–1499. doi: 10.1099/jgv.0.000468.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/jgv.0.000468</ArticleId><ArticleId IdType="pubmed">27031847</ArticleId></ArticleIdList></Reference><Reference><Citation>Souza C.K., Rajão D.S., Loving C.L., Gauger P.C., Pérez D.R., Vincent A.L. Age at Vaccination and Timing of Infection Do Not Alter Vaccine-Associated Enhanced Respiratory Disease in Influenza A Virus-Infected Pigs. Clin. Vaccine Immunol. 2016;23:470–482. doi: 10.1128/CVI.00563-15.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CVI.00563-15</ArticleId><ArticleId IdType="pmc">PMC4895012</ArticleId><ArticleId IdType="pubmed">27030585</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao T., Cai Y., Jiang Y., He X., Wei Y., Yu Y., Tian X. Vaccine adjuvants: Mechanisms and platforms. Signal Transduct. Target. Ther. 2023;8:283. doi: 10.1038/s41392-023-01557-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-023-01557-7</ArticleId><ArticleId IdType="pmc">PMC10356842</ArticleId><ArticleId IdType="pubmed">37468460</ArticleId></ArticleIdList></Reference><Reference><Citation>Joyce S., Okoye G.D., Driver J.P. Die Kämpfe únd schláchten-the struggles and battles of innate-like effector T lymphocytes with microbes. Front. Immunol. 2023;14:1117825. doi: 10.3389/fimmu.2023.1117825.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1117825</ArticleId><ArticleId IdType="pmc">PMC10165076</ArticleId><ArticleId IdType="pubmed">37168859</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayakawa Y., Takeda K., Yagita H., Van Kaer L., Saiki I., Okumura K. Differential regulation of Th1 and Th2 functions of NKT cells by CD28 and CD40 costimulatory pathways. J. Immunol. 2001;166:6012–6018. doi: 10.4049/jimmunol.166.10.6012.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.166.10.6012</ArticleId><ArticleId IdType="pubmed">11342617</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Kaer L., Parekh V.V., Wu L. Invariant natural killer T cells: Bridging innate and adaptive immunity. Cell Tissue Res. 2011;343:43–55. doi: 10.1007/s00441-010-1023-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00441-010-1023-3</ArticleId><ArticleId IdType="pmc">PMC3616393</ArticleId><ArticleId IdType="pubmed">20734065</ArticleId></ArticleIdList></Reference><Reference><Citation>Bendelac A., Savage P.B., Teyton L. The biology of NKT cells. Annu Rev. Immunol. 2007;25:297–336. doi: 10.1146/annurev.immunol.25.022106.141711.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.immunol.25.022106.141711</ArticleId><ArticleId IdType="pubmed">17150027</ArticleId></ArticleIdList></Reference><Reference><Citation>Emoto M., Emoto Y., Yoshizawa I., Kita E., Shimizu T., Hurwitz R., Brinkmann V., Kaufmann S.H. Alpha-GalCer ameliorates listeriosis by accelerating infiltration of Gr-1+ cells into the liver. Eur. J. Immunol. 2010;40:1328–1341. doi: 10.1002/eji.200939594.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/eji.200939594</ArticleId><ArticleId IdType="pubmed">20162550</ArticleId></ArticleIdList></Reference><Reference><Citation>Sidobre S., Naidenko O.V., Sim B.C., Gascoigne N.R., Garcia K.C., Kronenberg M. The V alpha 14 NKT cell TCR exhibits high-affinity binding to a glycolipid/CD1d complex. J. Immunol. 2002;169:1340–1348. doi: 10.4049/jimmunol.169.3.1340.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.169.3.1340</ArticleId><ArticleId IdType="pubmed">12133957</ArticleId></ArticleIdList></Reference><Reference><Citation>Speir M., Hermans I.F., Weinkove R. Engaging Natural Killer T Cells as ’Universal Helpers’ for Vaccination. Drugs. 2017;77:1–15. doi: 10.1007/s40265-016-0675-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40265-016-0675-z</ArticleId><ArticleId IdType="pubmed">28005229</ArticleId></ArticleIdList></Reference><Reference><Citation>Cerundolo V., Silk J.D., Masri S.H., Salio M. Harnessing invariant NKT cells in vaccination strategies. Nat. Rev. Immunol. 2009;9:28–38. doi: 10.1038/nri2451.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri2451</ArticleId><ArticleId IdType="pubmed">19079136</ArticleId></ArticleIdList></Reference><Reference><Citation>Burn O.K., Pankhurst T.E., Painter G.F., Connor L.M., Hermans I.F. Harnessing NKT cells for vaccination. Oxf. Open Immunol. 2021;2:iqab013. doi: 10.1093/oxfimm/iqab013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/oxfimm/iqab013</ArticleId><ArticleId IdType="pmc">PMC9914585</ArticleId><ArticleId IdType="pubmed">36845569</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujii S.-i., Yamasaki S., Sato Y., Shimizu K. Vaccine Designs Utilizing Invariant NKT-Licensed Antigen-Presenting Cells Provide NKT or T Cell Help for B Cell Responses. Front. Immunol. 2018;9:01267. doi: 10.3389/fimmu.2018.01267.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.01267</ArticleId><ArticleId IdType="pmc">PMC5995044</ArticleId><ArticleId IdType="pubmed">29915600</ArticleId></ArticleIdList></Reference><Reference><Citation>Barral P., Eckl-Dorna J., Harwood N.E., De Santo C., Salio M., Illarionov P., Besra G.S., Cerundolo V., Batista F.D. B cell receptor-mediated uptake of CD1d-restricted antigen augments antibody responses by recruiting invariant NKT cell help in vivo. Proc. Natl. Acad. Sci. USA. 2008;105:8345–8350. doi: 10.1073/pnas.0802968105.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0802968105</ArticleId><ArticleId IdType="pmc">PMC2448839</ArticleId><ArticleId IdType="pubmed">18550831</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang P.P., Barral P., Fitch J., Pratama A., Ma C.S., Kallies A., Hogan J.J., Cerundolo V., Tangye S.G., Bittman R., et al. Identification of Bcl-6-dependent follicular helper NKT cells that provide cognate help for B cell responses. Nat. Immunol. 2011;13:35–43. doi: 10.1038/ni.2166.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni.2166</ArticleId><ArticleId IdType="pubmed">22120117</ArticleId></ArticleIdList></Reference><Reference><Citation>Driver J.P., de Carvalho Madrid D.M., Gu W., Artiaga B.L., Richt J.A. Modulation of Immune Responses to Influenza A Virus Vaccines by Natural Killer T Cells. Front. Immunol. 2020;11:2172. doi: 10.3389/fimmu.2020.02172.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.02172</ArticleId><ArticleId IdType="pmc">PMC7606973</ArticleId><ArticleId IdType="pubmed">33193296</ArticleId></ArticleIdList></Reference><Reference><Citation>Sponseller B.A., Strait E., Jergens A., Trujillo J., Harmon K., Koster L., Jenkins-Moore M., Killian M., Swenson S., Bender H., et al. Influenza A pandemic (H1N1) 2009 virus infection in domestic cat. Emerg. Infect. Dis. 2010;16:534–537. doi: 10.3201/eid1603.091737.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid1603.091737</ArticleId><ArticleId IdType="pmc">PMC3322044</ArticleId><ArticleId IdType="pubmed">20202440</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO . WHO Manual on Animal Influenza Diagnosis and Surveillance. World Health Organization; Geneva, Switzerland: 2002.</Citation></Reference><Reference><Citation>Solórzano A., Webby R.J., Lager K.M., Janke B.H., García-Sastre A., Richt J.A. Mutations in the NS1 protein of swine influenza virus impair anti-interferon activity and confer attenuation in pigs. J. Virol. 2005;79:7535–7543. doi: 10.1128/JVI.79.12.7535-7543.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.79.12.7535-7543.2005</ArticleId><ArticleId IdType="pmc">PMC1143661</ArticleId><ArticleId IdType="pubmed">15919908</ArticleId></ArticleIdList></Reference><Reference><Citation>Artiaga B.L., Morozov I., Ransburgh R., Kwon T., Balaraman V., Indran S.V., De Carvalho Madrid D.M., Gu W., Henningson J., Ma W., et al. Evaluating α-galactosylceramide as an adjuvant for live attenuated influenza vaccines in pigs. Anim. Dis. 2022;2:19. doi: 10.1186/s44149-022-00051-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s44149-022-00051-x</ArticleId><ArticleId IdType="pmc">PMC9339466</ArticleId><ArticleId IdType="pubmed">35936354</ArticleId></ArticleIdList></Reference><Reference><Citation>Reed L.J., Muench H. A simple method for estimating fifty percent endpoints. Am. J. Epidemiol. 1938;27:493–497. doi: 10.1093/oxfordjournals.aje.a118408.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/oxfordjournals.aje.a118408</ArticleId></ArticleIdList></Reference><Reference><Citation>Artiaga B.L., Whitener R.L., Staples C.R., Driver J.P. Adjuvant effects of therapeutic glycolipids administered to a cohort of NKT cell-diverse pigs. Vet. Immunol. Immunopathol. 2014;162:1–13. doi: 10.1016/j.vetimm.2014.09.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vetimm.2014.09.006</ArticleId><ArticleId IdType="pubmed">25441499</ArticleId></ArticleIdList></Reference><Reference><Citation>Artiaga B.L., Yang G., Hackmann T.J., Liu Q., Richt J.A., Salek-Ardakani S., Castleman W.L., Lednicky J.A., Driver J.P. α-Galactosylceramide protects swine against influenza infection when administered as a vaccine adjuvant. Sci. Rep. 2016;6:23593. doi: 10.1038/srep23593.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep23593</ArticleId><ArticleId IdType="pmc">PMC4804283</ArticleId><ArticleId IdType="pubmed">27004737</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou B., Wentworth D.E. Influenza A virus molecular virology techniques. Methods Mol. Biol. 2012;865:175–192. doi: 10.1007/978-1-61779-621-0_11.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-61779-621-0_11</ArticleId><ArticleId IdType="pubmed">22528160</ArticleId></ArticleIdList></Reference><Reference><Citation>Vita R., Mahajan S., Overton J.A., Dhanda S.K., Martini S., Cantrell J.R., Wheeler D.K., Sette A., Peters B. The Immune Epitope Database (IEDB): 2018 update. Nucleic Acids Res. 2019;47:D339–D343. doi: 10.1093/nar/gky1006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gky1006</ArticleId><ArticleId IdType="pmc">PMC6324067</ArticleId><ArticleId IdType="pubmed">30357391</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitikoon P., Gauger P.C., Vincent A.L. Hemagglutinin inhibition assay with swine sera. Methods Mol. Biol. 2014;1161:295–301. doi: 10.1007/978-1-4939-0758-8_24.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-4939-0758-8_24</ArticleId><ArticleId IdType="pubmed">24899438</ArticleId></ArticleIdList></Reference><Reference><Citation>Sunwoo S.Y., Schotsaert M., Morozov I., Davis A.S., Li Y., Lee J., McDowell C., Meade P., Nachbagauer R., García-Sastre A., et al. A Universal Influenza Virus Vaccine Candidate Tested in a Pig Vaccination-Infection Model in the Presence of Maternal Antibodies. Vaccines. 2018;6:64. doi: 10.3390/vaccines6030064.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines6030064</ArticleId><ArticleId IdType="pmc">PMC6161263</ArticleId><ArticleId IdType="pubmed">30223475</ArticleId></ArticleIdList></Reference><Reference><Citation>Halbur P.G., Paul P.S., Frey M.L., Landgraf J., Eernisse K., Meng X.J., Lum M.A., Andrews J.J., Rathje J.A. Comparison of the pathogenicity of two US porcine reproductive and respiratory syndrome virus isolates with that of the Lelystad virus. Vet. Pathol. 1995;32:648–660. doi: 10.1177/030098589503200606.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/030098589503200606</ArticleId><ArticleId IdType="pubmed">8592800</ArticleId></ArticleIdList></Reference><Reference><Citation>Pescovitz M.D., Hsu S.M., Katz S.I., Lunney J.K., Shimada S., Sachs D.H. Characterization of a porcine CD1-specific mAb that distinguishes CD4/CD8 double-positive thymic from peripheral T lymphocytes. Tissue Antigens. 1990;35:151–156. doi: 10.1111/j.1399-0039.1990.tb01772.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1399-0039.1990.tb01772.x</ArticleId><ArticleId IdType="pubmed">1695393</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang H., Parkhouse R.M. Phenotypic classification of porcine lymphocyte subpopulations in blood and lymphoid tissues. Immunology. 1996;89:76–83. doi: 10.1046/j.1365-2567.1996.d01-705.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2567.1996.d01-705.x</ArticleId><ArticleId IdType="pmc">PMC1456652</ArticleId><ArticleId IdType="pubmed">8911143</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuckermann F.A., Gaskins H.R. Distribution of porcine CD4/CD8 double-positive T lymphocytes in mucosa-associated lymphoid tissues. Immunology. 1996;87:493–499. doi: 10.1046/j.1365-2567.1996.494570.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2567.1996.494570.x</ArticleId><ArticleId IdType="pmc">PMC1384122</ArticleId><ArticleId IdType="pubmed">8778039</ArticleId></ArticleIdList></Reference><Reference><Citation>Iyoda T., Yamasaki S., Ueda S., Shimizu K., Fujii S.I. Natural Killer T and Natural Killer Cell-Based Immunotherapy Strategies Targeting Cancer. Biomolecules. 2023;13:348. doi: 10.3390/biom13020348.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biom13020348</ArticleId><ArticleId IdType="pmc">PMC9953375</ArticleId><ArticleId IdType="pubmed">36830717</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson A., Lukacs J.D., Johnston B. The Current Landscape of NKT Cell Immunotherapy and the Hills Ahead. Cancers. 2021;13:5174. doi: 10.3390/cancers13205174.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cancers13205174</ArticleId><ArticleId IdType="pmc">PMC8533824</ArticleId><ArticleId IdType="pubmed">34680322</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandez C.S., Jegaskanda S., Godfrey D.I., Kent S.J. In-vivo stimulation of macaque natural killer T cells with α-galactosylceramide. Clin. Exp. Immunol. 2013;173:480–492. doi: 10.1111/cei.12132.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cei.12132</ArticleId><ArticleId IdType="pmc">PMC3949636</ArticleId><ArticleId IdType="pubmed">23656283</ArticleId></ArticleIdList></Reference><Reference><Citation>Schäfer A., Hühr J., Schwaiger T., Dorhoi A., Mettenleiter T.C., Blome S., Schröder C., Blohm U. Porcine Invariant Natural Killer T Cells: Functional Profiling and Dynamics in Steady State and Viral Infections. Front Immunol. 2019;10:1380. doi: 10.3389/fimmu.2019.01380.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.01380</ArticleId><ArticleId IdType="pmc">PMC6611438</ArticleId><ArticleId IdType="pubmed">31316500</ArticleId></ArticleIdList></Reference><Reference><Citation>Thierry A., Robin A., Giraud S., Minouflet S., Barra A., Bridoux F., Hauet T., Touchard G., Herbelin A., Gombert J.M. Identification of invariant natural killer T cells in porcine peripheral blood. Vet. Immunol. Immunopathol. 2012;149:272–279. doi: 10.1016/j.vetimm.2012.06.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vetimm.2012.06.023</ArticleId><ArticleId IdType="pubmed">22939274</ArticleId></ArticleIdList></Reference><Reference><Citation>Renukaradhya G.J., Manickam C., Khatri M., Rauf A., Li X., Tsuji M., Rajashekara G., Dwivedi V. Functional invariant NKT cells in pig lungs regulate the airway hyperreactivity: A potential animal model. J. Clin. Immunol. 2011;31:228–239. doi: 10.1007/s10875-010-9476-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10875-010-9476-4</ArticleId><ArticleId IdType="pmc">PMC4450678</ArticleId><ArticleId IdType="pubmed">21042929</ArticleId></ArticleIdList></Reference><Reference><Citation>Madrid D.M.C., Gu W., Artiaga B.L., Yang G., Loeb J., Hawkins I.K., Castleman W.L., Lednicky J.A., Richt J.A., Driver J.P. Comparison of oseltamivir and α-galactosylceramide for reducing disease and transmission in pigs infected with 2009 H1N1 pandemic influenza virus. Front. Vet. Sci. 2022;9:999507. doi: 10.3389/fvets.2022.999507.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fvets.2022.999507</ArticleId><ArticleId IdType="pmc">PMC9635317</ArticleId><ArticleId IdType="pubmed">36337191</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu W., Madrid D.M.D., Yang G., Artiaga B.L., Loeb J.C., Castleman W.L., Richt J.A., Lednicky J.A., Driver J.P. Unaltered influenza disease outcomes in swine prophylactically treated with α-galactosylceramide. Dev. Comp. Immunol. 2021;114:103843. doi: 10.1016/j.dci.2020.103843.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dci.2020.103843</ArticleId><ArticleId IdType="pmc">PMC8119227</ArticleId><ArticleId IdType="pubmed">32871161</ArticleId></ArticleIdList></Reference><Reference><Citation>Artiaga B.L., Yang G., Hutchinson T.E., Loeb J.C., Richt J.A., Lednicky J.A., Salek-Ardakani S., Driver J.P. Rapid control of pandemic H1N1 influenza by targeting NKT-cells. Sci. Rep. 2016;6:37999. doi: 10.1038/srep37999.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep37999</ArticleId><ArticleId IdType="pmc">PMC5126553</ArticleId><ArticleId IdType="pubmed">27897246</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheon I.S., Son Y.M., Sun J. Tissue-resident memory T cells and lung immunopathology. Immunol. Rev. 2023;316:63–83. doi: 10.1111/imr.13201.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imr.13201</ArticleId><ArticleId IdType="pmc">PMC10524334</ArticleId><ArticleId IdType="pubmed">37014096</ArticleId></ArticleIdList></Reference><Reference><Citation>Xue K.S., Moncla L.H., Bedford T., Bloom J.D. Within-Host Evolution of Human Influenza Virus. Trends Microbiol. 2018;26:781–793. doi: 10.1016/j.tim.2018.02.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tim.2018.02.007</ArticleId><ArticleId IdType="pmc">PMC6097882</ArticleId><ArticleId IdType="pubmed">29534854</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>